Citation: | XU Zhiyang, TIAN Wenliang, FU Xue, TANG Ping, CHEN Dandan, WANG Fang, CHEN Shaoqian, MENG Xiaoli, LIU Linxiang, SUN Ling. Expression of USP22 in Patients with Acute Leukemia and Its Clinical Signifi cance[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 366-369. DOI: 10.3971/j.issn.1000-8578.2014.04.018 |
[1] |
Lee HJ, Kim MS, Shin JM, et al. The expression patterns of deubiquitinating enzymes, USP22 and Usp22[J]. Gene Expr Patterns, 2006, 6(3): 277-84.
|
[2] |
Zhang XY, Varthi M, Sykes SM, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression[J]. Mol Cell, 2008, 29(1): 102-11.
|
[3] |
Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway[J]. Cell Cycle, 2006, 5(11): 1208-16.
|
[4] |
Zhang Y,Yao L,Zhang X,et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer[J]. J Cancer Res Clin Oncol, 2011, 137(8):1245-53.
|
[5] |
Hu J, Liu YL, Piao SL, et al. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer[J]. Lung Cancer, 2012, 77(3): 593-9.
|
[6] |
Yang DD, Cui BB, Sun LY, et al. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma[J]. Cell Biochem Biophys, 20 11,61(3): 703-10.
|
[7] |
Zhou F,Cui BB,Liu YL,et al. Expression and clinical signifi cance of usp22 and ki67 in colorectal carcinoma[J].Zhong Liu Fang Zhi Yan Jiu ,2012,39(1):68-70.[ 周飞,崔滨滨,刘彦龙,等.USP22 和ki67在大肠癌组织中的表达及其临床意义[J].肿瘤防治研 究,2012,39(1):68-70.]
|
[8] |
Zhang ZN,Shen T. Haematology diagnostic and curative standard[M].Beijing:Science Press,2009: 103-34.[张之南, 沈 悌. 血液病诊断及疗效标准[M].北京:科学出版社, 2009: 103-34.]
|
[9] |
Ao N,Liu YQ.Research advances in the function of USP22 in the occurrence and development of tumor[J].Ji Chu Yi Xue Yu Lin Chuang,2012, 32(10): 1235-8.[ 敖宁,刘玉琴. USP22在肿瘤发 生发展中的作用研究进展[J]. 基础医学与临床, 2012,32(10): 12 35-8.]
|
[10] |
Liu Y,Yang Y,Xu H, et al. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas[J]. Diagn Mol Pathol, 2010, 19 (4): 194-200.
|
[11] |
Liu YL, Jiang SX, Yang YM, et al. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway[J]. Cell Biochem Biophys, 2012,62(1): 229-35.
|
[12] |
Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelialmesenchymal transition in human nasopharyngeal epithelial cells[J]. J Clin Invest, 2009,119(12): 3626-36.
|
1. |
牛莉莉,阎萍,李建明,闫文萍. 术前淋巴细胞与单核细胞比值在乳腺癌预后评估的探讨. 新疆医学. 2024(01): 21-23+48 .
![]() | |
2. |
汤婵丽,李英,章小飞. 术前中性粒细胞与淋巴细胞计数比值联合糖类抗原153对乳腺癌的诊断价值. 中国妇幼保健. 2023(02): 237-240 .
![]() | |
3. |
郭风,李景亮,杨淑娟,刘源溪. 乳腺癌患者中医证型、VEGF-C、雌激素受体表达与预后的相关性. 实用癌症杂志. 2023(03): 383-386 .
![]() | |
4. |
刘翔,杜璐迪,舒敬德. 炎性细胞比值对乳腺癌新辅助化疗疗效和疾病进展风险预测的价值. 中国卫生检验杂志. 2023(06): 703-707 .
![]() | |
5. |
汪传一,陈志亚,徐彬博,李小庆. 保乳手术与改良根治术对早期乳腺癌患者的治疗效果比较. 癌症进展. 2023(09): 1012-1015 .
![]() | |
6. |
王海龙,王运昌,张芳,张周龙,梅文娟. 超声引导下穿刺活检及NLR、PLR对乳腺癌腋窝淋巴结转移的诊断价值. 实用癌症杂志. 2023(11): 1891-1894 .
![]() | |
7. |
张明,陈晓玉. 系统免疫炎性指数 嗜酸性粒细胞-淋巴细胞比率与乳腺癌病理特征的相关性分析. 山西医药杂志. 2022(02): 194-197 .
![]() | |
8. |
代焕,朱正秋,陈嘉劼. 系统免疫炎症指数、预后营养指数对Ⅲ~Ⅳ期非小细胞肺癌一线化疗患者预后的预测价值. 医学研究杂志. 2022(03): 121-126 .
![]() | |
9. |
周银芳,朱鸿. 平均血小板体积淋巴细胞比值与乳腺癌新辅助化疗疗效关联性分析. 贵州医药. 2022(07): 1051-1053 .
![]() | |
10. |
徐晓飞,李阳,陈凌云,代贺阳,薛姣姣,李庆霞. 预后营养指数和控制营养状态在乳腺癌中的研究进展. 肿瘤防治研究. 2022(09): 961-964 .
![]() | |
11. |
叶尔哈那提·胡杜斯,阿尔恒别克·吐汗拜,艾克拜尔·尤努斯. NLR、LMR和PLR与骨肉瘤预后的关系. 肿瘤防治研究. 2021(04): 381-386 .
![]() | |
12. |
陈景芝,马丽丽,冯艳玉. 循环肿瘤细胞、微小核糖核酸-1246、糖类抗原153在乳腺癌中的表达及其与临床病理特征和预后的关系. 实用临床医药杂志. 2021(22): 17-20+25 .
![]() |